Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk

Inverse associations of Parkinson's disease (PD) with cigarette smoking, coffee drinking, and nonsteroidal anti‐inflammatory drug (NSAID) use have been reported individually, but their joint effects have not been examined. To quantify associations with PD for the individual, two‐way and three‐way combinations of these factors, a case–control association study with 1,186 PD patients and 928 controls was conducted. The study setting was the NeuroGenetics Research Consortium. Subjects completed a structured questionnaire regarding smoking, coffee, and NSAID consumption. Odds ratios were calculated using unconditional logistic regression. Smoking, coffee, and over the counter NSAID use as individual factors exhibited significantly reduced risks of 20% to 30%. The two‐way and three‐way combinations were associated with risk reduction of 37% to 49%, and 62%, respectively. Smoking and coffee exhibited significant inverse risk trends with increasing cumulative exposures, suggesting dose–response relations. With respect to the combination of all three exposures, persons who were at the highest exposure strata for smoking and coffee and used NSAIDs had an estimated 87% reduction in risk (OR = 0.13, 95% CI = 0.06–0.29). Whether this finding reflects true biologic protection needs to be investigated. © 2007 Movement Disorder Society

[1]  A. Hofman,et al.  Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease , 2007, Neuroepidemiology.

[2]  J. Nutt,et al.  Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease , 2007, Annals of neurology.

[3]  K. Marder,et al.  Pooled analysis of tobacco use and risk of Parkinson disease. , 2007, Archives of neurology.

[4]  J. Langston,et al.  Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates , 2006, Journal of neurochemistry.

[5]  Aldo Quattrone,et al.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.

[6]  W. Kukull,et al.  Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[7]  M. Hernán,et al.  Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease , 2006, Neurology.

[8]  J. Nutt,et al.  Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinics , 2006, Movement disorders : official journal of the Movement Disorder Society.

[9]  Eric Jacobs,et al.  Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease , 2005, Annals of neurology.

[10]  A J Lees,et al.  Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  D. Casper,et al.  Dopaminergic neurotoxicity by 6‐OHDA and MPP+: Differential requirement for neuronal cyclooxygenase activity , 2005, Journal of neuroscience research.

[12]  Honglei Chen,et al.  The Tau Gene Haplotype H1 Confers a Susceptibility to Parkinson’s Disease , 2004, European Neurology.

[13]  M. Thun,et al.  Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. , 2004, American journal of epidemiology.

[14]  E. Hirsch,et al.  Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin , 2003, Brain Research.

[15]  B. Liu,et al.  Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. , 2003, Environmental health perspectives.

[16]  T. Foroud,et al.  Reliability of reported age at onset for Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[17]  Miguel A Hernán,et al.  A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.

[18]  A. Ascherio,et al.  Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. , 2002, Neurology.

[19]  Harvey Checkoway,et al.  Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. , 2002, American journal of epidemiology.

[20]  M. Quik,et al.  Nicotine administration reduces striatal MPP+ levels in mice , 2001, Brain Research.

[21]  W. Willett,et al.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women , 2001, Annals of neurology.

[22]  D. Casper,et al.  Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro , 2000, Neuroscience Letters.

[23]  C. Tanner,et al.  Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.

[24]  L. Golbe,et al.  Dopamine‐related personality traits in Parkinson's disease , 1993, Neurology.

[25]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[26]  J. Ioannidis,et al.  Collaborative Analysis of (cid:1) -Synuclein Gene Promoter Variability and Parkinson Disease , 2006 .

[27]  H. Petrovitch,et al.  Current Evidence for Neuroprotective Effects of Nicotine and Caffeine Against Parkinson’s Disease , 2001, Drugs & aging.

[28]  K. Marder,et al.  Reliability of symptom onset assessment in Parkinson's disease , 1994, Movement disorders : official journal of the Movement Disorder Society.